ClinicalTrials.gg

Program

pitavastatin

Also written as “Pitavastatin”, “Pitavastatin (NK-104)” and “NK-104-CR”.

Its studies are mostly in Hypercholesterolemia · Hyperlipidemias · Renal Insufficiency · Dyslipidemias · Diabetes Mellitus, Type 2, led by 5 companies.

Furthest: phase 4, since Dec 18, 200929 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Kowa180 open or runningphase 4since Dec 18, 2009Nov 4, 2005none ahead
JW Pharmaceutical80 open or runningphase 4since Mar 18, 2008Mar 18, 2008none ahead
Merck10 open or runningphase 1since Oct 12, 2017Oct 12, 2017none ahead
Orient Pharma10 open or runningphase 3since Oct 16, 2012Oct 16, 2012none ahead
tai-tien-pharmaceuticals-co-ltd10 open or runningphase 3since Jun 29, 2011Jun 29, 2011none ahead

Also a collaborator on its studies: orient-europharma-co-ltd, kowa-pharmaceuticals-america-inc and Eli Lilly.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 14 studies since Nov 4, 2005.

  1. Jan 25, 2010Phase 4 study in Healthy VolunteersKowa · NCT01057433 · 24 enrolled · United States
  2. Jul 19, 2010Phase 4 study in HypercholesterolemiaJW Pharmaceutical · NCT01166633 · 200 enrolled
  3. Dec 7, 2010Phase 4 study in Primary DyslipidemiaKowa · NCT01256476 · 328 enrolled · United States
  4. Feb 18, 2011Phase 4 study in DyslipidemiasKowa · NCT01301066 · 252 enrolled · United States
  5. Jun 29, 2011tai-tien-pharmaceuticals-co-ltd's first study: phase 3 study in HyperlipidemiasNew to tai-tien-pharmaceuticals-co-ltdtai-tien-pharmaceuticals-co-ltd · NCT01386853 · 200 enrolled · Taiwan
  6. Jul 26, 2011Phase 1 study in HyperlipidemiasJW Pharmaceutical · NCT01406431 · 48 enrolled · Korea, Republic of
  7. Aug 22, 20112 phase 4 studies in HealthyKowa · NCT01422382, NCT01422369
  8. May 2, 2012Phase 1 study in Metabolic SyndromeKowa · NCT01595828 · 14 enrolled · United Kingdom
  9. Oct 16, 2012Orient Pharma's first study: phase 3 study in HypercholesterolemiaNew to Orient PharmaOrient Pharma · NCT01710007 · 202 enrolled · Taiwan
  10. Feb 4, 2014Phase 4 study in HyperlipidemiasJW Pharmaceutical · NCT02056847 · 313 enrolled · Korea, Republic of
  11. Jan 28, 2016Phase 3 study in HyperlipidemiasKowa · NCT02670434 · United States
  12. Jun 10, 2016Phase 3 study in HyperlipidemiasKowa · NCT02799758 · United States
  13. Oct 12, 2017Merck's first study: phase 1 study in Renal InsufficiencyNew to MerckMerck · NCT03311841 · 32 enrolled · United States
  14. Oct 6, 2020Phase 3 study in Primary HypercholesterolemiaJW Pharmaceutical · NCT04584736 · 283 enrolled · Korea, Republic of

TargetBeta

HMGCR →read by rule
“HMG-CoA reductase inhibitor; HMG-CoA reductase inhibitor; HMG-CoA reductase inhibitor”ChEMBL 37, by rule

Other programs on HMGCR

ProgramCompanyFurthest phaseStudies
AtorvastatinruleViatrisphase 4186
rosuvastatinruleAstraZenecaphase 4184
SimvastatinruleOrganonphase 4100

Studies

All 29 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT04584736Primary Hypercholesterolemia · Korea, Republic of3CompletedJW PharmaceuticalJul 16, 2020283
NCT03311841Renal Insufficiency · United States1CompletedMerckAug 2, 201832
NCT02799758Hyperlipidemias · United States3WithdrawnKowaJul 20170
NCT02670434Hyperlipidemias · United States3WithdrawnKowaJul 20170
NCT02056847Hyperlipidemias · Korea, Republic of4CompletedJW PharmaceuticalMay 2017313
NCT01710007Hypercholesterolemia · Taiwan3CompletedOrient PharmaSep 2012202
NCT01595828Metabolic Syndrome · United Kingdom1CompletedKowaJun 201214
NCT01422382Healthy · United States4CompletedKowaJun 201128
NCT01422369Healthy · United States4CompletedKowaJun 201128
NCT01406431Hyperlipidemias · Korea, Republic of1CompletedJW PharmaceuticalAug 201148
NCT01386853Hyperlipidemias · Taiwan3UNKNOWNtai-tien-pharmaceuticals-co-ltdMar 2012200
NCT01301066Dyslipidemias · United States4CompletedKowaMar 2013252
NCT01256476Primary Dyslipidemia · United States4CompletedKowaJun 2011328
NCT01166633Hypercholesterolemia4CompletedJW PharmaceuticalNov 2010200
NCT01057433Healthy Volunteers · United States4CompletedKowaDec 201024
NCT01043094Renal Insufficiency · United States4CompletedKowaApr 201016
NCT00889226Hypercholesterolemia With Type2DM4CompletedJW PharmaceuticalMay 2009161
NCT00786734Angina, Stable · Korea, Republic of4WithdrawnJW PharmaceuticalMay 20090
NCT00701285Heart Failure · Korea, Republic of4CompletedJW PharmaceuticalMay 201370
NCT00640276Hypercholesterolemia · Korea, Republic of4CompletedJW PharmaceuticalFeb 2011187
NCT00344370Diabetes Mellitus, Type 2 · Denmark, Germany, India and more3CompletedKowaApr 2008214
NCT00344175Hypercholesterolemia · Denmark, Netherlands, Spain and more3CompletedKowaAug 2007178
NCT00330876Hypercholesterolemia · Denmark, Germany, Israel and more3CompletedKowaDec 2007545
NCT00325780Hypercholesterolemia · Denmark, Finland, Germany and more3CompletedKowaNov 20071,355
NCT00309751Diabetes Mellitus, Type 2 · Denmark, Germany, India and more3CompletedKowaJun 2007418
NCT00309738Hypercholesterolemia · Denmark, Netherlands, Spain and more3CompletedKowaOct 2006355
NCT00257686Hypercholesterolemia · Denmark, Germany, Israel and more3CompletedKowaMay 2006962
NCT00309777Hypercholesterolemia · Finland, Italy, Norway and more3CompletedKowaOct 2006857
NCT00249249Dyslipidemias · Denmark, Finland, Germany and more3CompletedKowa830

How it is read

Names in the registry

  • “Pitavastatin”, 18 entries
  • “pitavastatin”, 8 entries
  • “Pitavastatin (NK-104)”, 3 entries
  • “NK-104-CR”, 2 entries
  • “pitavastatin single dose combined with ceftobiprole”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.